Pediatrix Medical Group, Inc. (MD Quick QuoteMD - Free Report) is well-poised for growth, benefiting from stronger cash collections, a favorable payer mix and higher patient acuity in neonatology. Strategic acquisitions are adding further support to revenue and earnings growth. Shares of MD have risen 9.7% in the year-to-date period against the industry’s decline of 10.1%.

Headquartered in Sunrise, FL, the company holds a market capitalization of $1.9 billion. MD provides newborn, maternal-fetal, radiology, pediatric cardiology and other pediatric subspecialty physician services. The company’s forward P/E ratio of 10.67 is lower than the industry average of 14.74.

Given its solid prospects, Pediatrix Medical currently carries a Zacks Rank #2 (Buy).

Where Do Estimates for MD Stand?

The Zacks Consensus Estimate for Pediatrix Medical’s 2026 earnings is pegged at $2.20 per share, indicating a 7.8% year-over-year rise. In the past seven days, it has witnessed two upward estimate revisions against none in the opposite direction. Furthermore, the consensus mark for revenues is pegged at $1.9 billion for 2026. It beat earnings estimates in three of the past four quarters and missed once, with an average surprise of 21.3%.

Pediatrix Medical is benefiting from higher same-unit revenues and growth in same-unit pricing supported by improved payer mix, solid RCM cash collections, increased patient acuity and neonatology and higher administrative fees from hospital contracts. In the first quarter of 2026, same-unit revenues increased 4.4% year over year.

Clinical quality remains a major growth driver for MD’s healthcare platform. Its extensive hospital network and specialized focus on neonatal and maternal care continue to strengthen partnerships with healthcare systems across the country. The company’s scale and established presence across multiple service lines provide opportunities to expand care offerings and deepen relationships with existing hospital partners.

To strengthen care delivery and operational performance, Pediatrix Medical recently added experienced medical leaders with expertise in neonatal medicine, patient safety, quality improvement and artificial intelligence applications in healthcare. The company is using data-driven strategies and evidence-based clinical practices to improve patient outcomes, reduce care variation and enhance efficiency across its network.

Pediatrix Medical is also pursuing long-term expansion opportunities through telehealth services and broader obstetrics offerings across the country. Recently acquired practices also contributed positively to performance, supporting both revenue growth and profitability during the quarter. In addition, the company introduced a share price-based compensation initiative for clinician leaders to create stronger alignment between physicians and long-term business performance.

Its disciplined capital deployment is reflected in its strong return on invested capital (ROIC) of 11.5%, above the industry average of 6.5%, highlighting efficient capital allocation and value creation. During the first quarter of 2026, the company repurchased 1 million shares for $19.9 million. As of March 31, 2026, $146.3 million was available under the buyback program.

MD: Risks to Watch

However, there are some factors that investors should keep a careful eye on.

Pediatrix Medical continues to operate with elevated leverage, with net debt of $590.8 million substantially exceeding its $205.8 million cash balance as of March 31, 2026. The high debt load increases interest expense sensitivity and constrains financial flexibility. Its total debt-to-EBITDA ratio of 2.46X is broadly in line with the industry average, limiting the company’s capacity to absorb earnings volatility or pursue growth initiatives without additional balance sheet strain.

Other Stocks to Consider

Some other top-ranked stocks in the Medical space are BrightSpring Health Services, Inc. (BTSG Quick QuoteBTSG - Free Report) , Globus Medical, Inc. (GMED Quick QuoteGMED - Free Report) and West Pharmaceutical Services, Inc. (WST Quick QuoteWST - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for BrightSpring Health Services’ current-year earnings of $1.64 per share has witnessed five upward revisions in the past 30 days against no movement in the opposite direction. BTSG beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 14.6%. The consensus estimate for current-year revenues is pegged at $15.1 billion, suggesting 16.6% year-over-year growth.

The Zacks Consensus Estimate for Globus Medical’s current-year earnings of $4.66 per share has witnessed one upward revision in the past seven days, against no movement in the opposite direction. GMED Pharmaceuticals beat earnings estimates in each of the trailing four quarters, with the average surprise being 26.3%. The consensus estimate for current-year revenues is pegged at $3.2 billion, suggesting 8.8% year-over-year growth.

The Zacks Consensus Estimate for West Pharmaceutical Services’ current-year earnings of $8.50 per share has witnessed six upward revisions in the past 30 days, against no movement in the opposite direction. WST beat earnings estimates in each of the trailing four quarters, with an average surprise of 19.4%. The consensus estimate for current-year revenues is pegged at $3.3 billion, suggesting 7.8% year-over-year growth.